RxDoctor Payments DataLook up a doctor →

Gary McCracken, MD

Dermatology · Scottsdale, AZNPI 1093884843

Payments from drug & device makers

$615,483in general payments, 2019–2025

Across 260 payments — averaging $2367.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$273K
  • Boehringer Ingelheim$199K
  • Eli Lilly$102K
  • Incyte Corporation$27K
  • Boehringer Ingelheim Canada Ltd.ltee$8K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$3K
  • plus $4K from 28 others
$66,164in research payments, 2019–2025

Across 2 payments — averaging $33,082 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$66K

What the payments were for

  • Food & beverage$4,14998%
  • Education$952%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$615,483 in reported general payments places this provider in the 95th percentile of 305 dermatology providers in Arizona.

See all dermatology providers in Arizona

Medicare billing

Part B allowed, 2024
$859,796
Medicare patients
2,834
Services billed
15,987

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab13$46,276
Dupixent PenDupilumab11$39,062
Fluocinonide208$7,296
Doxycycline Hyclate69$3,694
Clobetasol Propionate53$3,024
Metronidazole60$2,913
Triamcinolone Acetonide238$2,241
Ketoconazole149$2,137
Acitretin13$2,122
CiclopiroxCiclopirox Olamine65$1,730
Clindamycin Phosphate39$1,688
Minocycline Hcl45$1,280
Ampicillin Trihydrate39$1,209
Fluorouracil13$816
ValacyclovirValacyclovir Hcl43$777

Paid to pharmacies, not to this prescriber.

Other dermatology in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →